1. Home
  2. NTHI vs GHI Comparison

NTHI vs GHI Comparison

Compare NTHI & GHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NeOnc Technologies Holdings Inc.

NTHI

NeOnc Technologies Holdings Inc.

HOLD

Current Price

$3.44

Market Cap

114.6M

Sector

Health Care

ML Signal

HOLD

Logo Greystone Housing Impact Investors LP Beneficial Unit Certificates representing assignments of limited partnership interests

GHI

Greystone Housing Impact Investors LP Beneficial Unit Certificates representing assignments of limited partnership interests

HOLD

Current Price

$5.32

Market Cap

121.3M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
NTHI
GHI
Founded
2008
1998
Country
United States
United States
Employees
5
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance: Consumer Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
114.6M
121.3M
IPO Year
N/A
1998

Fundamental Metrics

Financial Performance
Metric
NTHI
GHI
Price
$3.44
$5.32
Analyst Decision
Strong Buy
Buy
Analyst Count
1
3
Target Price
$15.00
$10.50
AVG Volume (30 Days)
65.4K
47.1K
Earning Date
05-19-2026
05-12-2026
Dividend Yield
N/A
22.93%
EPS Growth
N/A
N/A
EPS
N/A
0.01
Revenue
N/A
$85,389,766.00
Revenue This Year
N/A
$273.95
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$512.00
Revenue Growth
N/A
N/A
52 Week Low
$3.01
$4.71
52 Week High
$12.99
$11.45

Technical Indicators

Market Signals
Indicator
NTHI
GHI
Relative Strength Index (RSI) 35.86 51.27
Support Level $3.01 $5.05
Resistance Level $4.59 $5.52
Average True Range (ATR) 0.38 0.16
MACD -0.03 -0.03
Stochastic Oscillator 25.55 70.94

Price Performance

Historical Comparison
NTHI
GHI

About NTHI NeOnc Technologies Holdings Inc.

NeOnc Technologies Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing novel molecular technologies for the targeted delivery of therapeutics to treat central nervous system diseases. The company is developing drug delivery methods and drug candidates for intracranial malignancies such as gliomas, glioblastoma, and meningioma. Its lead product candidates include NEO100, an intranasal drug delivery therapy for brain cancer patients, and NEO212, an oral chemical conjugate designed to enhance treatment for glioblastoma.

About GHI Greystone Housing Impact Investors LP Beneficial Unit Certificates representing assignments of limited partnership interests

Greystone Housing Impact Investors LP engaged in acquiring a portfolio of mortgage revenue bonds (MRBs) that are issued by state and local housing authorities to provide construction and/or permanent financing for affordable multifamily housing, seniors housing, and commercial properties. It has four reportable segments, namely Affordable Multifamily MRB Investments, Seniors and Skilled Nursing MRB Investments, MF Properties, and Market-Rate Joint Venture Investments. It generates the majority of its revenue from the Affordable Multifamily MRB Investments segment.

Share on Social Networks: